L&C Bio Co., Ltd

KOSDAQ 290650.KQ

L&C Bio Co., Ltd EBITDA for the year ending December 31, 2023: USD 10.29 M

L&C Bio Co., Ltd EBITDA is USD 10.29 M for the year ending December 31, 2023, a -8.56% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

L&C Bio Co., Ltd EBITDA for the year ending December 31, 2022 was USD 11.26 M, a -16.32% change year over year.
L&C Bio Co., Ltd EBITDA for the year ending December 31, 2021 was USD 13.45 M, a 64.44% change year over year.
L&C Bio Co., Ltd EBITDA for the year ending December 31, 2020 was USD 8.18 M, a -6.20% change year over year.
L&C Bio Co., Ltd EBITDA for the year ending December 31, 2019 was USD 8.72 M, a 52.65% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

KOSDAQ: 290650.KQ

L&C Bio Co., Ltd

CEO	Mr. Chul Lee Whan
IPO Date	Nov. 1, 2018
Location	South Korea
Headquarters	Suntechcity
Employees	122
Sector	Health Care
Industries Biotechnology Cosmetics Pharmaceuticals Research & Consulting

Description

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years